trending Market Intelligence /marketintelligence/en/news-insights/trending/_DXZzjbpa4jMaALLEqKNfw2 content esgSubNav
In This List

US judge may reject Novelion unit's deal with DOJ

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


US judge may reject Novelion unit's deal with DOJ

U.S. District Judge William Young may reject the plea agreement between Aegerion Pharmaceuticals Inc. and the U.S. Department of Justice, Reuters reported.

In September, the Novelion Therapeutics Inc. unit agreed to plead guilty to charges relating to its high-cholesterol drug Juxtapid and pay $36 million to resolve criminal and civil liability arising from the charges.

Young did not issue a definitive rejection of the plea agreement at a court hearing in Boston but noted that his instinct was to reject the deal, the news outlet reported.